Reactogenicity and Safety of Two Doses of GlaxoSmithKline (GSK) Biologicals Oral Live Attenuated Liquid Human Rotavirus (HRV) Vaccine 444563, in Healthy Infants.

Trial Profile

Reactogenicity and Safety of Two Doses of GlaxoSmithKline (GSK) Biologicals Oral Live Attenuated Liquid Human Rotavirus (HRV) Vaccine 444563, in Healthy Infants.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 May 2017

At a glance

  • Drugs Rotavirus vaccine (Primary)
  • Indications Rotavirus infections
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Jan 2011 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
    • 09 Jul 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top